Grifols is a global company in the health sector that markets its products in more than 100 countries and has a direct presence in more than 30 countries. The company’s class A shares have been listed on the Spanish Stock Exchange (MCE:GRF) since 2006 and have been part of the Ibex-35 since 2008. In 2011, the company listed non-voting class B shares on the Mercado Continuo (MCE:GRF.P) and in NASDAQ-United States via ADRs (NASDAQ: GRFS).
Grifols has become one of the largest plasma companies and in recent years has built up a strong network of plasma donation centers in the United States, Europe, Egypt and Canada, which has enabled it to expand and diversify its access to plasma. With the plasma obtained, Grifols produces essential medicines to treat chronic, rare and sometimes very serious diseases. As a recognized leader in transfusion medicine, the company has a comprehensive portfolio of solutions designed to improve safety from donation to transfusion. In addition, it supplies biological products for non-therapeutic use.
Grifols has the necessary infrastructure and experience in planning future needs to maintain a path of sustainable growth based on continuous improvement and the optimization of processes and costs. Its solid manufacturing presence, mainly in the United States and Spain, has enabled to promote a scaled global dimension with a distinctly global dimension, as well as to the growing market demand.
You can find more information about Grifols on www.grifols.com